The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.
Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.
North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2019, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111
The pharma and healthcare sector has significantly advanced in the recent years and is expected to register steady revenue growth over the forecast period owing to rapid innovations in medical technology, increasing investments, rising healthcare expenditure and high adoption of advanced products and systems. Factors such as rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and neurological disorders across the globe, rising cases of coronavirus, improving healthcare infrastructure and research facilities, and increasing adoption of remote patient monitoring services and home care settings are expected to fuel global market revenue growth over the forecast period. In addition, increasing number of hospitals and ambulatory care centers worldwide, high demand for personalized medicine, increasing investments in drug discovery and growing investments by public and private sectors are expected to drive global market growth in the coming years.
The report also focuses on details of each market player including its global position, financial standing, revenue generation, company overview, product service portfolio. The Non-Alcoholic Steatohepatitis (NASH) market is extremely competitive and consists of several key players at regional and global level. Key players are focused on adopting various strategies such as new product launches, mergers and acquisitions, investments in RD, partnerships, joint ventures and collaborations to strengthen their market position and enhance product portfolio.
Leading companies operating in the market are:
Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1111
The report also offers detailed insights about market segmentation based on type, application and regional bifurcation:
Non-Alcoholic Steatohepatitis (NASH) Market Segmentation:
Disease cause (Revenue USD Million; 2018-2028)
- Heart Disease
- High blood Lipid
- Type 2 diabetes
Drug Type (Revenue, USD Million, 2018-2028)
- Vitamin E Pioglitazone
End-user Outlook (Revenue, USD; 2018-2028)
- Homecare Settings
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- South Africa
- Rest of MEA
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1111
Thank you for reading the report. Kindly note that we also offer customized reports according to the client requirement. Contact us to know more about the customization feature and our team will provide you with the best customized report.
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.